Cilostazol Doesn't Prevent Periprocedural MI in ACS

This article originally appeared here.
Share this content:
Cilostazol Doesn't Prevent Periprocedural MI in ACS
Cilostazol Doesn't Prevent Periprocedural MI in ACS

FRIDAY, May 6, 2016 (HealthDay News) -- For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), adjunctive loading dose of cilostazol is not associated with prevention of periprocedural myocardial infarction (PMI), according to a study published online May 1 in Cardiovascular Therapeutics.

Ling-Xia Xu, from the Second Hospital of Tianjin Medical University in China, and colleagues randomized patients with ACS undergoing PCI to receive loading doses of dual antiplatelet therapy (aspirin plus clopidogrel; DAPT group, 57 patients) or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; TAPT group, 56 patients). Patients in the TAPT group received one week of adjunctive cilostazol.

The researchers found that the incidence of PMI was not significantly different in the TAPT and DAPT groups (32.1 and 47.4 percent, respectively; P = 0.098). Among antiplatelet-naive patients, TAPT correlated with a significant decrease in PMI incidence, compared with DAPT (17.9 versus 42.9 percent; P = 0.042). The incidences of PMI were similar among antiplatelet-treated patients (46.4 versus 51.7 percent; P = 0.698). There was an independent correlation for antiplatelet treatment versus antiplatelet naivety with PMI (hazard ratio, 2.45; 95 percent confidence interval, 1.09 to 5.52). TAPT versus DAPT was not an independent protective factor for PMI (hazard ratio, 0.51; 95 percent confidence interval, 0.23 to 1.14).

"TAPT with adjunctive cilostazol was not associated with lower incidence of PCI-related PMI in patients with ACS," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

High Costs Associated With Physician Burnout, Attrition

High Costs Associated With Physician Burnout, Attrition

Economic loss at Stanford over two years expected to range from $15.5 million to $55.5 million

Insulin Doesn't Prevent Diabetes in Relatives of T1DM Patients

Insulin Doesn't Prevent Diabetes in Relatives of T1DM ...

Oral insulin doesn't delay onset in autoantibody-positive relatives of patients with type 1 diabetes

Workplace Sexual Harassment Ongoing in Women, Up for Men

Workplace Sexual Harassment Ongoing in Women, Up for ...

Women report more adverse effects after SH than men, but SH can trigger depression, anxiety in men

is free, fast, and customized just for you!

Already a member?

Sign In Now »